Overview

Gender

male

Investor Type

Investment Partner

Peter Villax is Bionova Capital’s Chairman. He joined Hovione in 1982 as a computer programmer and led Hovione’s computerization, then switched to pharmaceutical development in 1990 and soon became interested in in pulmonary delivery. His disposable dry-powder inhaler TwinCaps, licensed to Daiichi Sankyo for the delivery of Influenza drug Inavir®, continues to be the only commercial device of its kind in the world, and has helped Daiichi Sankyo become the market leader in influenza products in Japan. He acquired significant experience as an inventor of devices, as a patentholder and as licensor of technology patents. In 2013 together with Miguel Calado, he was involved in a 7-figure royalty monetization deal with a US-based financial company, under which Hovione sold the future income streams earned under a license agreement.

Peter Villax is also active in civic duties, as president of the Family Business Association in Portugal, a member of three University faculty boards (Pharmacy in U. Coimbra, Medicine in U.Lisbon and the Institute of Chemical and Biological Technology in U.Nova) as well as of other organizations. He is a lecturer and a frequent speaker at scientific, academic and business conferences and an ocasional participant in TV programmes.